Other

Estimated Fair Value

Medtronic Estimated Fair Value increased by 2.8% to $7.26B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 8.3%, from $6.70B to $7.26B. Over 3 years (FY 2022 to FY 2025), Estimated Fair Value shows relatively stable performance with a -0.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionOther
CategoryLiquidity
SignalHigher is better
VolatilityVolatile
First reportedQ4 2022
Last reportedQ3 2026Feb 24, 2026

How to read this metric

An increase relative to amortized cost indicates unrealized gains, while a decrease indicates unrealized losses due to market volatility or interest rate changes.

Detailed definition

The current market value of debt securities classified as available-for-sale, excluding accrued interest. This metric pr...

Peer comparison

Standard for insurers; peers with similar duration profiles will show similar sensitivity to market interest rate changes.

Metric ID: other_debt_securities_available_for_sale_excluding_accru_fbe99d

Historical Data

15 periods
 Q4 '22Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Value$6.89B$6.64B$6.65B$6.45B$6.57B$6.46B$6.70B$6.72B$6.53B$6.59B$6.70B$6.75B$6.86B$7.06B$7.26B
QoQ Change-3.7%+0.2%-3.0%+1.9%-1.7%+3.8%+0.3%-2.9%+0.9%+1.6%+0.8%+1.6%+2.9%+2.8%
YoY Change-6.4%-2.7%+0.8%+4.2%-0.6%+2.1%-0.1%+0.4%+5.0%+7.1%+8.3%
Range$6.45B$7.26B
CAGR+1.5%
Avg YoY Growth+1.7%
Median YoY Growth+0.8%
Current Streak6 quarters growth

Estimated Fair Value at Other Companies

Frequently Asked Questions

What is Medtronic's estimated fair value?
Medtronic (MDT) reported estimated fair value of $7.26B in Q4 2025.
How has Medtronic's estimated fair value changed year-over-year?
Medtronic's estimated fair value increased by 8.3% year-over-year, from $6.70B to $7.26B.
What is the long-term trend for Medtronic's estimated fair value?
Over 3 years (2022 to 2025), Medtronic's estimated fair value has grown at a -0.7% compound annual growth rate (CAGR), from $6.89B to $6.75B.
What does estimated fair value mean?
The current market price of the company's available-for-sale debt investments.